NasdaqGM:IOVABiotechs
Iovance Biotherapeutics (IOVA) Raises US$350 Million in Equity Offering
Iovance Biotherapeutics (IOVA) saw its share price increase by 27% last quarter, coinciding with several key developments. Health Canada's conditional approval of Amtagvi for melanoma treatment, coupled with reinforced revenue guidance and a substantial $350 million equity offering, bolstered investor confidence. The broader market trends, with major indexes posting gains despite some sector-specific declines, provided a supportive environment for the company's stock performance. While the...